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Degradation of interstitial collagens probably takes 
place through different enzymatic mechanisms than deg­
radation of basement membrane and pericellular colla­
gens. Interstitial collagens are resorbed under patholog­
ical and physiological conditions by collagenases which 
function extracellularly and cleave polypeptide chains 
in the collagen triple helix at specific loci resulting in 
solubilization from the fibril. Production of collagenase 
in humans is ascribable to fibroblast-like cells which can 
be stimulated to synthesize new enzyme for release out­
side of the cell. In several inflammatory conditions, such 
as rheumatoid synovitis, modulation of collagenase pro­
duction is mediated by interactions with surrounding 
inflammatory cells. Monocyte-macrophages produce a 
stimulatory factor, which has homologies with interleu­
kin 1, which not only increases collagenase synthesis but 
also PGE2 synthesis. The PGE2 in turn has profound 
effects on cellular function. Production of the mononu­
clear cell factor is modulated by several interactions 
including T lymphocytes and T lymphocyte products, 
collagen of the extracellular matrix and the Fc portion 
of immunoglobulins. It is probable, from analogies with 
other stimulants such as phorbol myristate acetate, that 
the increase in collagen synthesis is controlled at the 
level of transcription. Further regulation of collagenase 
action outside of the cell is probably accomplished by 
proteolytic activation of a latent collagenase zymogen 
and interactions with inhibitory proteins also produced 
by cells in the local environment of the resorptive proc­
ess. 
In the course of physiological remodeling and in pathological 
states, the collagen of the extracellular matrix is degraded and 
resorbed. The possible mechanisms of these resorption pro­
cesses, which have been extensively investigated, are not the 
same for the different collagen types and are subject to specific 
tissue regulation. Considerable evidence has been obtained 
which indicates, under most circumstances, that the degrada­
tion of the interstitial collagens is mediated by specific colla­
genases which act near neutral pH and are capable of cleaving 
the molecules at specific loci in the polypeptide chains across 
the helix [1-4]. The action of these collagenases results in 
solubilization of the molecules at the surface of the fibrils and 
eventual dissolution of the fibrils. It is possible that proteases 
other than the collagenases have a synergistic role in degrada­
tion of the fibrils (and fibers) by cleaving peptide bonds in the 
telopeptide regions adjacent to sites of intermolecular crosslinks 
[5,6]. Elastase-type enzymes may not only cleave within telo­
peptide regions of types I and III collagens but are also capable 
of breaking peptide bonds within the type III collagen helix 
[7]. A potential role for elastases in degrading type IV and type 
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V collagens has also been proposed [8,9]. Enzymes with sub­
strate specificity for types IV and V collagen have been identi­
fied in polymorphonuclear leukocytes [9] as well as macro­
phages [10]. Type V collagen has also been shown to be suscep­
tible to cleavage with purified thrombin, at temperatures 
>34°C, and it is possible that thrombin could play a role in 
degradation of this pericellular collagen during some types of 
tissue injury [11]. The more specific animal collagenases have 
little action on the type IV and V collagens. 
In this discussion, however, my attention will be directed 
primarily towards a consideration of the degradation of the 
interstitial collagens which takes place predominantly extracel­
lularly. Although there have been examples of processes in 
which collagen fibrils appear to be phagocytosed and have been 
identified within cells, it is probable that this intracellular 
digestion is not the critial event in conditions of collagen re­
sorption [2]. 
It is likely that collagen resorption is an important process 
during growth of most organs in which the matrix must be 
removed to allow for increments in size. Once adulthood is 
reached, however, collagen resorption takes place very slowly 
in most tissues, with the exception of bone, where remodelling 
is a continuous process. Another exception is the involuting 
uterus. A considerable proportion of the increase in uterine 
weight during pregnancy is accounted for by collagen deposition 
and the decrease in mass of the uterus after delivery of the fetus 
is therefore associated with collagen removal which correlates 
with tissue levels of collagenase [12,13]. In bone, however, 
correlations between mineralized tissue resorption and levels of 
collagenase and/or pro collagenase have not been established 
[14]. 
There are several pathological states in which collage no lysis 
is obvious in vivo and can be demonstrated in cultures of the 
involved tissue. Examples of some of these conditions are listed 
in Table I. A detailed description of one of these conditions, 
epidermolysis bullosa appears elsewhere in this volume [15]. I 
should like to use rheumatoid arthritis as an example of patho­
logical collagen resorption, to describe some approaches to the 
understanding of biochemical mechanisms and cellular controls. 
The degradation of collagenous structures in rheumatoid ar­
thritis serves as a useful model for studying resorption, for 
reasons such as those listed in Table II. There are several 
aspects to this problem which could be considered in detail, on 
the basis of results of studies reported from many different 
laboratories, which are probably pertinent to the interpretation 
of mechanisms in other inflammatory conditions such as cho­
lesteatoma, chemical burns of the cornea, or chronic periodontal 
disease. My attention however, will be directed primarily to­
wards a description of what is known concerning cellular control 
of collagenase production. 
We have emphasized that the major sites of collagen resorp­
tion in chronic inflammatory joint disease are in regions contig­
uous with the apparently proliferative mass of chronic inflam­
matory cells. This inflammatory cell mass is seen initially at 
the margins of the joint, especially in the pockets formed by 
the reflection of the synovial lining [16,17]. Mineralized and 
nonmineralized collagenous components are apparently eroded 
due to the actions of the inflammatory cells which burrow 
beneath the cartilage and bone or work over the surface of the 
articular cartilage (pannus). The inflammatory tissue mass is 
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T ABLE I. Some conditions associated with collagen degradation 
and collagenase production 
1. Corneal ulceration (e.g., alkali burns) 
2. Epidermolysis bullosa 
3. Cholesteatoma 
4. Chronic periodontal disease 
5. Inflammatory joint disease (rheumatoid arthritis, psoriatic arthrop­
athy) 
6. Other destructive joint disease (pigmented villonodular synovitis, 
hemophiliac arthropathy) 
------------ ---------- ----------
TABLE II. Some observations which provide evidence for a role of 
collagenase in the destructive lesion of rheumatoid arthritis 
1. Collagen resorption in vivo iH largely extracellular. Collagenase 
released by synovial explant� and dispersed cells is released into 
medium and not stored. 
2. Collagenolysis of synovial explants is proportional to collagenase 
release. 
3. Collagenase with properties similar to that produced in culture can 
be found in some rheumatoid synovial fluids. 
4. Collagen substrates degraded in vivo are cleaved by synovial colla­
genase in vitro. 
.f). Reaction products similar to those found in l'itro have been identi­
fied in vivo. 
6. Immunohistological localization of collagenase corresponds to areas 
(e.g., pannus-cartilage junction) where resorption occurs. 
heterogeneous and is comprised of many cell types. Polymor­
phonuclear leukocytes, however, are normally sparse in the 
granulation tissue although they are abundant in the synovial 
fluid. 
Explants of the inflammatory synovial tii,;sue release large 
amounts of apparently active collagenase when cultured in the 
absence of serum [18,19]. This enzyme activity has all of the 
characteristics of the other animal collagenases and cleaves a 
glycyl-isoleucine bond between residues 771 and 772 of the 
helical portion of the interstitial collagen chains [4]. It is im­
portant to note that the release of enzyme activity by these 
ex plants correlates with the release of soluble collagen peptides 
derived from the interstitial portions of the explant itself [20]. 
Inhibitors are also present in the culture media and account in 
part for the lag period, occasionally as long as several days, 
before enzyme activity can be detected. Since other proteases, 
besides collagenases, are produced by synovial explants, such 
as a neutral protease which cleaves denatured collagen (gelatin) 
but not native collagen [21], it is quite possible that the only 
collagenase produced by the cells is an inactive zymogen which 
requires proteolytic activation. The regulation, extracellularly, 
of the ultimate action of collagenases by the cellular production 
of activators and inhibitors must be of great importance [22]. 
Although evidence has been offered supporting the concept of 
active enzyme complexed with an inhibitor to account for latent 
collagenase in several different culture systems [22], the recent 
demonstration that, at least in rabbit synovial fibroblasts, col­
lagenase is synthesized and secreted as a single polypeptide 
zymogen is more compelling. The latter demonstration has 
been acco:nplished by translating the rabbit synovial fibroblast 
mRNA in a cell-free wheat germ system [23]. 
It had been shown in the early studies of rheumatoid synovial 
collagenase that enzyme is not stored in cells and its release 
into culture media is presumably dependent upon new RNA 
synthesis (probably mRNA) in view of the inhibition with 
actinomycin D [2,20]. This concept has been supported by 
recent evidence which indicates that stimulation of collagenase 
synthesis with substances such as phorbol myristate acetate in 
rabbit synovial fibroblasts is associated with increased levels of 
translatable collagenase mRNA [24]. Thus, control of collagen­
ase production in other situations may also be at the level of 
transcription. 
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Other cellular controls of collagenase synthesis and secretion 
are also known. It was apparent at the time that the animal 
collagenases were first identified by Gross and Lapiere [25], 
that living cells are required for continued collagenase release 
and that intracellular storage is minimal. Similar observations 
were made in the rheumatoid synovial explant system [18,19] 
where simple freezing and thawing of tissue prior to culture 
eliminates collagenase release. Furthermore, any interference 
with cellular metabolism, such as inhibition of glycolysis with 
iodoacetate, also blocks collagenase production [20]. On the 
other hand, agents which interact with microtubule structures 
such as colchicine in low concentrations (0.1 .ug/ml) stimulate 
collagenase release and probably synthesis as well [20]. Cyto­
chalasin B [26] also increases collagenase synthesis in cultured 
synovial cells as does phorbol myristate acetate [27]. 
Although the evidence is good that collagenase is synthesized 
and secreted as a single polypeptide zymogen, the cellular 
production of enzyme inhibitors must influence the extent of 
extracellular collagenolysis. Several protein inhibitors have 
been identified such as one from human tendon cultures with 
Mr of "'25,000 [28] and another from dermal fibroblasts with 
Mr of (\)31,000 [29]. Some of the inhibitors described have 
narrow specificity apparently directed primarily towards colla­
genase [28]. The so-called ,82-anticollagenase characterized by 
Woolley, Roberts, and Evanson [30] only inhibits animal col­
lagenase among the proteases tested. Other inhibitors which 
have a broad spectrum, e.g., the circulating u2-macroglobulin, 
bind and block proteolytic activity of several enzymes including 
collagenase. It is probable that important cellular controls of 
collagenolysis are located at the level of inhibitor production. 
For example, it has recently been shown that whereas free 
protease inhibitor is released by several cultured human tissues, 
including normal synovium, no free inhibitor is detected in 
rheumatoid synovial culture medium [31] . Furthermore, the 
amounts of free inhibitor in synovial culture medium are in­
creased in the presence of glucocorticoids [32]. Assuming that 
the collagenase is secreted in the form of an inactive zymogen 
some mechanism of activation must be proposed. Although 
latent enzyme can be activated by proteases such as trypsin, 
other enzymes must fulfill this role at sites of inflammation. 
Plasmin is a reasonable candidate, since it can be generated 
from plasminogen activator produced by rheumatoid synovial 
cells [3il]. 
A major aspect in understanding biological control of colla­
genase would be to determine which of the heterogeneous 
population of inflammatory cells in the rheumatoid synovium 
are responsible for secretion of collagenase. In addition it ap­
pears important to ask whether these cells are unique in this 
capacity to produce this enzyme and whether they function 
alone or interact with other cells in their environment. When 
we first assayed for collagenase in medium from fibroblasts 
grown from rheumatoid synovial explants, none could be de­
tected although enzyme could be found in other fibroblast 
cultures under certain conditions [34,35]. Subsequently we 
changed our approach, based upon the possibility that the 
explant method for culturing fibroblasts selects for cells with 
the capacity to grow under certain conditions rather than for 
cells with particular functional properties. 
We therefore harvested cells from these rheumatoid explants, 
not by waiting for outgrowth at the margins, but by dissociating 
them from the original explant with clostridial collagenase 
followed by trypsin, and found that the adherent population 
produces extraordinary amounts of active collagenase, when 
the cultures are maintained in the absence of serum [36]. These 
observations suggested either that the system is self-activating, 
or there is relatively little inhibitor relative to enzyme. If, 
however, the cells are maintained in the presence of serum no 
collagenase is detected, unless the latent enzyme is activated 
with trypsin. These adherent rheumatoid synovial cells grow 
slowly but continue to produce collagenase in large amounts for 
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several weeks in primary culture. In addition, cultures of these 
cells also produce relatively enormous amounts of prostaglan­
dins, almost exclusively PGE2 [36). In the primary cultures, the 
predominant cell is a large cell with several dendritic processes. 
Smaller cells are also present in primary culture, many of which 
are macro phages with traditional macrophage markers, such as 
surface receptors for the Fc portion of immunoglobulins. Wool­
ley et al [37,38] have demonstrated that these stellate (dendri­
tic) cells show positive immunofluorescent staining using an 
antibody to synovial collagenase, with the fluorescence extend­
ing out into the processes, whereas other cells present, which 
have a more typical fibroblast morphology, do not fluoresce. 
These observations suggest that the collagenase-making cells 
are the stellate (dendritic) cells. When such adherent cells are 
maintained for longer periods (weeks to months) in culture, the 
levels of collagenase and prostaglandin decrease and a smaller 
proportion of the population demonstrates the stellate appear­
ance. We have recently obtained evidence which suggests that 
the morphological appearance of the cells is due to effects of 
the high ambient concentrations of prostaglandins [39). When 
prostaglandin synthesis is inhibited with indomethacin, the 
morphology changes to resemble fibroblasts; addition of exog­
enous prostaglandin or 8-bromo cAMP then causes the cells to 
revert to the stellate form. Such changes in morphology are 
also produced by exposing the later passage cells to monocyte 
products, which I will describe shortly. Reports of changes in 
cell shape induced by cyclic nucleotides were described earlier 
in other systems by Willingham and Pastan [40] and by Ortiz, 
Yamada, and Hsie [41). 
When the synovial cells are passaged or maintained in culture 
for several weeks, the levels of collagenase and prostaglandin 
decrease; in some cultures, there is barely detectable collagen­
ase activity after four or five passages. During this period, the 
smaller round cells (macrophages) that do not stain by immu­
nofluorescence for collagenase gradually decrease in number 
and eventually cannot be detected. We therefore reasoned that 
if we were losing macrophages from culture, they could be 
added back to the synovial cells to restore the levels of colla­
genase and PGE2• When monocytes are isolated from human 
peripheral blood and conditioned media examined for collagen­
ase there is no detectable activity. In contrast, a similar number 
of adherent synovial cells produce significant collagenase. When 
monocytes are co cultivated with the synovial cells, the latter 
are stimulated to increase collagenase levels [42,43], with a 
dose-related increase in medium PGEz levels. Cell-cell contact 
is not necessary, since conditioned media from the macrophages 
are capable of stimulating the synovial cells. We have termed 
the substance responsible, mononuclear cell factor, or MCF. 
When mononuclear cells from peripheral blood are purified 
using Ficoll/diatrizoate gradients and placed in culture, addi­
tion of increasing volumes of mononuclear cell media to the 
synovial cells yields increases in medium levels of collagenase 
and prostaglandins [44,45). Indomethacin, at concentrations of 
0.1-1.0 [lM which markedly inhibits prostaglandin synthesis, 
usually does not affect collagenase levels. These two products 
of the cultured synovial cells can therefore be manipulated 
independently. 
Although cultured monocyte-macrophages alone can stimu­
late collagenase activity by synovial cells, interactions with T 
lymphocytes in the presence of lectins or antigens result in 
greater stimulating activity [46]. We now have obtained evi­
dence that a soluble product produced by T cells is responsible 
for the effects on the macrophages, although T lymphocytes 
alone yield little if any stimulating activity (EP Amento, JT 
Kurnick, A Epstein, SM Krane, in preparation). It is possible 
that in the process of separating monocyte-macrophages from 
other cells in the peripheral blood, activation occurs. Presently, 
we isolate the monocyte-macrophages by selecting for adherent 
cells; this selection process may itself be sufficient to increase 
production of the stimulating factor. 
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Since macrophages have receptors for immunoglobulins on 
their surface, we also reasoned that addition of immunoglobu­
lins to the monocyte-macrophage cultures could increase 
release of the stimulating factor [47). Purified, aggregated im­
munoglobulin G strikingly augments production of MCF, as­
sayed by measurement of the ability of monocyte-macrophage 
conditioned media to increase PGE2 and collagenase levels in 
synovial cell cultures, in addition to increasing PGE2 synthesis 
by the monocyte-macrophages, themselves. This effect appears 
to reside in the Fc region (probably the carboxy terminal 
domain) of the immunoglobulin molecule. 
Another substance that can increase MCF production by 
monocyte-macrophages is endotoxin. However, addition of the 
antibiotic polymyxin B, which complexes the lipopolysaccha­
ride, blunts biological effects of endotoxin. On the other hand, 
the stimulating capacity of the purified Fc fragments is not 
affected by addition of polymyxin B to the cultured cells [47]. 
Thus, the effects of the Fc fragments are probably not explained 
by contamination with endotoxin, although endotoxin, pro­
duced by bacteria, may be important in modulating inflamma­
tory responses in disease states including rheumatoid arthritis. 
The possibility that interactions of matrix components with 
the macrophages might influence the production of MCF was 
approached by separating mononuclear cells from peripheral 
blood and incubating them with collagens dried down on the 
surface of the culture tubes [48). Part of the rationale for these 
experiments is derived from results of experiments of Trentham, 
Townes and Kang [49] who demonstrated induction of arthritis 
in animals injected with type II collagen in incomplete Freunds' 
adjuvant. In addition, patients with rheumatoid arthritis show 
evidence of cellular immunity to types II or III collagens, 
manifested by collagen-induced production of leukocyte migra­
tion inhibitory factor (LIF) [50). Recently, we observed that 
incubation of mononuclear cells or purified monocyte-macro­
phages with types II or III collagens enhances the production 
of MCF, but to a similar extent in cells from normal or rheu­
matoid subjects [48). 
CONCLUDING REMARKS 
These cell culture models thus provide a means for dissecting 
the complex controls that operate to regulate the levels of active 
extracellular collagenase under conditions of inflammation. It 
appears that in the heterogeneous population of cells in in­
flamed tissues (such as those in the rheumatoid synoviuml a 
modified fibroblast-like cell is responsible for collagenase pro­
duction. What determines when a cell begins to produce the 
enzyme and is subject to modulation by products of other cells 
is not yet known. Many different manipulations can alter col­
lagenase synthesis and release, including indirect effects on 
neighboring cells (monocyte-macrophages) resulting in produc­
tion of collagenase- and prostaglandin-stimulating factors. The 
most highly purified preparations of mononuclear cell factor 
stimulate both prostaglandin and collagenase by the target 
cells, and there must therefore be some common pathway for 
this effect. However, in some culture systems prostaglandin 
production can be blocked without altering collagenase levels. 
The stimulating factor derived from monocyte-macrophages 
has biological activity in systems where other mononuclear cell 
products have been shown to act. For example, highly purified 
preparations of interleukin 1 (lymphocyte activating factor) 
have stimulatory effects on collagenase and PGE2 production 
by synovial cells [51). Similarly, purified preparations of human 
MCF have interleukin 1 activity. Furthermore, products of 
corneal epithelial cells which stimulate stromal (fibroblast) cells 
to increase collagenase levels [52] may also have homologies 
with the monocyte-macrophage products. These many factors 
may ultimately exert control of collagenase synthesis at the 
level of transcription. However, interaction of cells with each 
other and the extracellular environment may also regulate 
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collagenase action by modulating the release of a host of inhib­
itors and activators. Many seemingly different pathological 
conditions of collagen degradation must share these common 
control mechanisms. 
I thank D. Malcuit for preparation of the manuscript. 
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